Historical Valuation
Evogene Ltd (EVGN) is now in the Overvalued zone, suggesting that its current forward PS ratio of 3.53 is considered Overvalued compared with the five-year average of -2.00. The fair price of Evogene Ltd (EVGN) is between 0.36 to 0.91 according to relative valuation methord. Compared to the current price of 1.10 USD , Evogene Ltd is Overvalued By 22.04%.
Relative Value
Fair Zone
0.36-0.91
Current Price：1.10
22.04%
Overvalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Evogene Ltd (EVGN) has a current Price-to-Book (P/B) ratio of 8.62. Compared to its 3-year average P/B ratio of 1.57 , the current P/B ratio is approximately 450.34% higher. Relative to its 5-year average P/B ratio of 1.64, the current P/B ratio is about 426.38% higher. Evogene Ltd (EVGN) has a Forward Free Cash Flow (FCF) yield of approximately -173.19%. Compared to its 3-year average FCF yield of -124.01%, the current FCF yield is approximately 39.66% lower. Relative to its 5-year average FCF yield of -93.20% , the current FCF yield is about 85.83% lower.
P/B
Median3y
1.57
Median5y
1.64
FCF Yield
Median3y
-124.01
Median5y
-93.20
Competitors Valuation Multiple
AI Analysis for EVGN
The average P/S ratio for EVGN competitors is 2.36, providing a benchmark for relative valuation. Evogene Ltd Corp (EVGN.O) exhibits a P/S ratio of 3.53, which is 49.57% above the industry average. Given its robust revenue growth of -82.07%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for EVGN
1Y
3Y
5Y
Market capitalization of EVGN increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of EVGN in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is EVGN currently overvalued or undervalued?
Evogene Ltd (EVGN) is now in the Overvalued zone, suggesting that its current forward PS ratio of 3.53 is considered Overvalued compared with the five-year average of -2.00. The fair price of Evogene Ltd (EVGN) is between 0.36 to 0.91 according to relative valuation methord. Compared to the current price of 1.10 USD , Evogene Ltd is Overvalued By 22.04% .
What is Evogene Ltd (EVGN) fair value?
EVGN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Evogene Ltd (EVGN) is between 0.36 to 0.91 according to relative valuation methord.
How does EVGN's valuation metrics compare to the industry average?
The average P/S ratio for EVGN's competitors is 2.36, providing a benchmark for relative valuation. Evogene Ltd Corp (EVGN) exhibits a P/S ratio of 3.53, which is 49.57% above the industry average. Given its robust revenue growth of -82.07%, this premium appears unsustainable.
What is the current P/B ratio for Evogene Ltd (EVGN) as of Jan 10 2026?
As of Jan 10 2026, Evogene Ltd (EVGN) has a P/B ratio of 8.62. This indicates that the market values EVGN at 8.62 times its book value.
What is the current FCF Yield for Evogene Ltd (EVGN) as of Jan 10 2026?
As of Jan 10 2026, Evogene Ltd (EVGN) has a FCF Yield of -173.19%. This means that for every dollar of Evogene Ltd’s market capitalization, the company generates -173.19 cents in free cash flow.
What is the current Forward P/E ratio for Evogene Ltd (EVGN) as of Jan 10 2026?
As of Jan 10 2026, Evogene Ltd (EVGN) has a Forward P/E ratio of -0.97. This means the market is willing to pay $-0.97 for every dollar of Evogene Ltd’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Evogene Ltd (EVGN) as of Jan 10 2026?
As of Jan 10 2026, Evogene Ltd (EVGN) has a Forward P/S ratio of 3.53. This means the market is valuing EVGN at $3.53 for every dollar of expected revenue over the next 12 months.